ResQ Medical

Treating Postpartum Hemorrhage

RESQ-MED

ResQ Medical is developing ALMA, a unique and innovative solution for treating Postpartum Hemorrhage (PPH) which is a life-threatening condition.
ALMA is attentive to the natural physiological mechanism of the uterus to deal with PPH.
Our approach with ALMA is to support the natural contraction of the uterus which in turn leads to the cessation of the bleeding as occurring naturally in any normal birth, and which doesn’t occur in the case of PPH. This innovative approach contrasts with the medical devices used today, which are based on inserting and inflating a balloon inside the uterine cavity- causing the uterus to expend against the natural mechanism of the body.

Market and Business Opportunity

The global market for postpartum hemorrhage devices expected to exceed $1.2 billion by 2025, CAGR of 5.4% over the forecast period. Further, the increasing rate of complications in pregnancies is a major factor driving the demand for postpartum hemorrhage devices, thereby contributing to market growth. It is estimated that nearly 3% of women giving birth in the United States bleed profusely after giving birth, meaning about 125,000 women a year in the US alone!

The Need

  • Before undertaking surgical operations, an attempt is made to stop the bleeding using dedicated devices, from which the go to device today is the Uterine balloon Tamponade (UBT) , an expanding balloon that compresses the bleeding vessels.
  • These solutions, are in essence working against the body’s natural mechanism to stop the bleeding, and have a limited success rate of only 65%.
    The market is seeking for an effective, reliable, easy to use and affordable solution!

    • Alma

    An innovative device which is attentive to the physiology and anatomy.
    The mode of operation mimics the contraction of the uterus for stopping the bleeding as occurring naturally in any normal birth.

    Advantages

    Our findings demonstrated that our Alma would help preserve life, end the bleeding empowering mothers against postpartum hemorrhage.

  • 1 Safe: Outstanding safety profile, fewer procedure-related adverse outcomes
  • 2 Effective: Fast physiologic control of abnormal Postpartum Uterine Bleeding, better and quicker bleeding cessation management than current solutions
  • 3 Easy and intuitive to use, for a variety of personnel with different medical background and expertise
  • 4 Cost effective

    • Seeking

    • Strategic collaboration
    • Investment for IND

    www.Resq-Med.com

    222

    Investment Profile

    • Validated patient need
    • Superior performance over current solutions
    • Highly experienced management team
    • strong IP

    Intellectual Property

    under construction .

    Management Team

    • Dr. Itamar Dach (DVM) CEO More than 13 years’ experience in the medical device arena, fulfilling a wide range of roles:Field marketing specialist, Upstream Marking-Philips Healthcare,
      Senior field service- Volcano,
      Product specialist-SyncRx,
      CRA and preclinical coordinator -Navotek Medical,
      CRE-Biocontrol Medical
    • Dr. Ali Mafra- Founder and entrepreneur specialized in Obstetrics and Gynecology. Earned his MD at Hadassah Medical school, Jerusalem. MPH at Haifa university, Israel. His main interest is fetal ultrasound.

      Dr. Mafra is senior doctor at Ob/Gyn department, Hillel Yaffe hospital, Hadera, Israel. During his carrier he participate in several congresses and won academic rewards including the best resident, Israel Medicine Association, 2014.

    • Prof. Dr. Michael Stark –Medical Advisor Specialized in Obstetrics and Gynecology. In the years 1983-2000 he was the director of Ob/Gyn department of the Misgav Ladach Hospital in Jerusalem, and between 2001 and 2009 the chairman of Gynecology at the HELIOS, European Hospital Group.
      Currently, the President of the New European Surgical Academy (NESA), an international inter-disciplinary surgical academy. Prof. Stark was the scientific advisor of the European novel Tele-surgical system, scientific and medical advisor of the ELSAN, a 120-hospital group in France and is a guest scientist at the Charite’s University hospital in Berlin.
    • Dr. Amnon Weichselbaum – CTO Over 20 years of hands-on experience in the Israeli medical
      start-up industry. Former CTO & Business Development Director at OFEK technological incubator,
      Migdal HaEmek, Israel.
      • CEO of Aqueduct Medical
      • Co-founder of Fertiligent, CBF Medical, Bacterioscan, Ferticool

    Contact

    Email – itamar@resq-med.com